文献速递肿瘤 PET/CT核素与放射性配体治疗

成纤维细胞激活蛋白抑制剂类放射性药物的临床总结:肿瘤及其他领域

Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-01-31

本文综述了基于成纤维细胞激活蛋白抑制剂(FAPI)的放射性药物的临床转化情况,涵盖其在肿瘤与非肿瘤疾病中的PET显像与放射治疗应用。作者指出,现有研究存在局限,妨碍了对FAPI类放射性药物的准确评价,但未来仍值得通过设计更好、人群更大的临床试验进一步探索其诊断与治疗价值。

要点

  • FAPI类放射性药物已用于多种肿瘤与非肿瘤疾病的PET显像和放射治疗研究。
  • 自2018年喹啉类FAP配体首次临床应用以来,FAPI显像与治疗的研究不断拓展。
  • 现有研究的局限妨碍了对FAPI类放射性药物的准确评价。

核心结论

  • FAPI类放射性药物在肿瘤或良性病变的诊断或治疗中具有价值,但现有研究的局限妨碍了对其的准确评价。
  • 未来值得通过设计更好、人群更大的临床试验进一步探索FAPI在诊断和治疗中的临床价值。

研究设计与样本

  • 本文为综述,汇总基于成纤维细胞激活蛋白抑制剂(FAPI)的放射性药物的临床转化情况,涵盖肿瘤与非肿瘤疾病。

主要发现

  • 成纤维细胞激活蛋白(FAP)是一种II型膜结合糖蛋白,在肿瘤相关成纤维细胞及伤口愈合/炎症部位的活化成纤维细胞中过表达。
  • 自2018年喹啉类FAP配体首次临床应用以来,基于FAPI的PET显像与放射治疗已在多种肿瘤与非肿瘤疾病中开展研究。
  • 综述强调FAPI放射性药物在肿瘤或良性病变诊断或治疗中的价值,并指出现有研究局限妨碍了准确评价。

局限性

  • 原文指出,现有研究的局限妨碍了对FAPI类放射性药物的准确评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fibroblast activation protein (FAP) is a type II membrane-bound glycoprotein which is overexpressed in cancer-associated fibroblasts and activated fibroblasts at wound healing/inflammatory sites. Since the first clinical application of quinoline-based FAP ligands in 2018, FAP inhibitor (FAPI)-based PET imaging and radiotherapy have been investigated for a wide variety of diseases, both cancerous and non-cancerous. As a consequence, promising strides have been made in particular to improve the understanding of FAPI-based PET imaging and the potential value of FAPI-based tumor radiotherapy. Herein, we present a comprehensive review of radiolabeled FAPI, including their clinical translation, in order to clarify the current and potential future role of this class of molecules in nuclear medicine. In particular, this review underlines the value of FAPI radiopharmaceuticals in the diagnosis or therapy of tumors or benign conditions. However, limitations in present studies have hampered a precise evaluation of FAPI radiopharmaceuticals. Despite this, it will likely be worthwhile to further explore the clinical value of FAPI in diagnosis and therapy through better-designed and larger-population clinical trials in the future.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Li M, Younis MH, Zhang Y, et al. Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond. Eur J Nucl Med Mol Imaging. 2022. PMID: 35098327. doi:10.1007/s00259-022-05706-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。